SHR0302 and Steroid As First Line Therapy for Chronic GVHD

Exclusion Criteria

• •Can not tolerate prednisone dose 1mg / kg / d or equivalent dose of other glucocorticoids for the treatment of cGVHD;
• •Receive any systemic treatment of cGVHD, except for corticosteroids that treat cGVHD within 72 hours prior to the signing of informed consent;
• •Patients with GVHD overlap syndrome (NIH criteria);
• •Treatment of acute GVHD has received other Jak inhibitors such as ruxolitinib;
• •Pregnant or lactating women;
• •The patient is judged by the investigator to have complications that may cause other risks;
• •The patient is receiving other study medications;
• •Patient blood routine: ANC \<1.0 × 109 / L or PLT \< 50 × 109 / L;
• •Non-GVHD-related liver damage: the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio is more than 3 times normal or the direct bilirubin normal value is more than 3 times;
• •Renal dysfunction: endogenous creatinine clearance (Ccr) \< 50mL/min or normal serum creatinine 1.5 times or more, regardless of hemodialysis treatment;
• •Uncontrolled infections: hemodynamic instability associated with infection, or new signs or signs of infection, or new infections in imaging, persistent fever without symptoms or signs and cannot be ruled out Infected person
• •People living with HIV;
• •Active hepatitis B (HBV), active hepatitis C (HCV) requires antiviral therapy; patients with HBV activation risk refer to patients with hepatitis B surface antigen-positive or core antibody-positive patients who are not treated with anti-HBV;
• •The patient's primary malignant disease recurs and the graft is rejected;
• •Those who are allergic to known JAK inhibitors.